Energy failure: Does it contribute to neurodegeneration?

Annals of Neurology

Volumn 74, Issue 4, 2013, Pages 506-516

  Pathak, Divya ^a   Berthet, Amandine ^a   Nakamura, Ken ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ADENOSINE TRIPHOSPHATE; GLUCOSE; NEUROTOXIN; REACTIVE OXYGEN METABOLITE; ROTENONE;

ALZHEIMER DISEASE; ARTICLE; BIOENERGY; BRAIN METABOLISM; CELL COMPARTMENTALIZATION; DEGENERATIVE DISEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENERGY FAILURE; GLUCOSE METABOLISM; HUMAN; IN VITRO STUDY; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL MYOPATHY; NERVE CELL NECROSIS; NERVE DEGENERATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PARKINSON DISEASE; PRIORITY JOURNAL;

ANIMALS; ENERGY METABOLISM; HUMANS; MITOCHONDRIA; MITOCHONDRIAL DISEASES; NEURODEGENERATIVE DISEASES; NEURONS;

EID: 84890108110     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24014     Document Type: Article

References (130)

1. Zheng B, Liao Z, Locascio JJ, et al. PGC-1alpha, a potential therapeutic target for early intervention in Parkinson's disease. Sci Transl Med 2010; 2: 52ra73.
2. Parihar MS, Brewer GJ,. Mitoenergetic failure in Alzheimer disease. Am J Physiol Cell Physiol 2007; 292: C8-C23.
3. Kapogiannis D, Mattson MP,. Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and Alzheimer's disease. Lancet Neurol 2011; 10: 187-198.
4. Mochel F, Haller RG,. Energy deficit in Huntington disease: why it matters. J Clin Invest 2011; 121: 493-499.
5. Nunnari J, Suomalainen A,. Mitochondria: in sickness and in health. Cell 2012; 148: 1145-1159.
6. Waagepetersen HS, Sonnewald U, Schousboe A,. Compartmentation of glutamine, glutamate, and GABA metabolism in neurons and astrocytes: functional implications. Neuroscientist 2003; 9: 398-403.
7. Vos M, Lauwers E, Verstreken P,. Synaptic mitochondria in synaptic transmission and organization of vesicle pools in health and disease. Front Synaptic Neurosci 2010; 2: 139.
8. Lieberthal W, Menza SA, Levine JS,. Graded ATP depletion can cause necrosis or apoptosis of cultured mouse proximal tubular cells. Am J Physiol 1998; 274 (2 pt 2): F315-F327.
9. Chiarugi A,. "Simple but not simpler": toward a unified picture of energy requirements in cell death. FASEB J 2005; 19: 1783-1788.
10. Valla J, Berndt JD, Gonzalez-Lima F,. Energy hypometabolism in posterior cingulate cortex of Alzheimer's patients: superficial laminar cytochrome oxidase associated with disease duration. J Neurosci 2001; 21: 4923-4930.
11. Tabrizi SJ, Cleeter MW, Xuereb J, et al. Biochemical abnormalities and excitotoxicity in Huntington's disease brain. Ann Neurol 1999; 45: 25-32.
12. Schapira AHV, Mann VM, Cooper JM, et al. Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J Neurochem 1990; 55: 2142-2145.
13. Azevedo FA, Carvalho LR, Grinberg LT, et al. Equal numbers of neuronal and nonneuronal cells make the human brain an isometrically scaled-up primate brain. J Comp Neurol 2009; 513: 532-541.
14. Vives-Bauza C, de Vries RL, Tocilescu MA, Przedborski S,. Is there a pathogenic role for mitochondria in Parkinson's disease? Parkinsonism Relat Disord 2009; 15 (suppl 3): S241-S244.
15. Liang WS, Reiman EM, Valla J, et al. Alzheimer's disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons. Proc Natl Acad Sci U S A 2008; 105: 4441-4446.
16. Telford JE, Kilbride SM, Davey GP,. Complex I is rate-limiting for oxygen consumption in the nerve terminal. J Biol Chem 2009; 284: 9109-9114.
17. Bender A, Krishnan KJ, Morris CM, et al. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat Genet 2006; 38: 515-517.
18. Coskun PE, Beal MF, Wallace DC,. Alzheimer's brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication. Proc Natl Acad Sci U S A 2004; 101: 10726-10731.
19. Mancuso M, Nardini M, Micheli D, et al. Lack of association between mtDNA haplogroups and Alzheimer's disease in Tuscany. Neurol Sci 2007; 28: 142-147.
20. Elson JL, Herrnstadt C, Preston G, et al. Does the mitochondrial genome play a role in the etiology of Alzheimer's disease? Hum Genet 2006; 119: 241-254.
21. Moraes CT, Sciacco M, Ricci E, et al. Phenotype-genotype correlations in skeletal muscle of patients with mtDNA deletions. Muscle Nerve 1995; 3: S150-S153.
22. Cui L, Jeong H, Borovecki F, et al. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 2006; 127: 59-69.
23. Qin W, Haroutunian V, Katsel P, et al. PGC-1alpha expression decreases in the Alzheimer disease brain as a function of dementia. Arch Neurol 2009; 66: 352-361.
24. Jenkins BG, Rosas HD, Chen YC, et al. 1H NMR spectroscopy studies of Huntington's disease: correlations with CAG repeat numbers. Neurology 1998; 50: 1357-1365.
25. Lodi R, Schapira AH, Manners D, et al. Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy. Ann Neurol 2000; 48: 72-76.
26. Saft C, Zange J, Andrich J, et al. Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease. Mov Disord 2005; 20: 674-679.
27. Mochel F, N'Guyen TM, Deelchand D, et al. Abnormal response to cortical activation in early stages of Huntington disease. Mov Disord 2012; 27: 907-910.
28. Hattingen E, Magerkurth J, Pilatus U, et al. Phosphorus and proton magnetic resonance spectroscopy demonstrates mitochondrial dysfunction in early and advanced Parkinson's disease. Brain 2009; 132 (pt 12): 3285-3297.
29. Stamelou M, Pilatus U, Reuss A, et al. In vivo evidence for cerebral depletion in high-energy phosphates in progressive supranuclear palsy. J Cereb Blood Flow Metab 2009; 29: 861-870.
30. Betarbet R, Sherer TB, MacKenzie G, et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 2000; 3: 1301-1306.
31. Langston JW, Ballard P, Tetrud JW, Irwin I,. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983; 219: 979-980.
32. Massieu L, Del Rio P, Montiel T,. Neurotoxicity of glutamate uptake inhibition in vivo: correlation with succinate dehydrogenase activity and prevention by energy substrates. Neuroscience 2001; 106: 669-677.
33. Brouillet E, Jacquard C, Bizat N, Blum D,. 3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease. J Neurochem 2005; 95: 1521-1540.
34. Greene JG, Greenamyre JT,. Characterization of the excitotoxic potential of the reversible succinate dehydrogenase inhibitor malonate. J Neurochem 1995; 64: 430-436.
35. Wang J, Xu Z, Fang H, et al. Gene expression profiling of MPP+-treated MN9D cells: a mechanism of toxicity study. Neurotoxicology 2007; 28: 979-987.
36. Choi WS, Kruse SE, Palmiter RD, Xia Z,. Mitochondrial complex I inhibition is not required for dopaminergic neuron death induced by rotenone, MPP+, or paraquat. Proc Natl Acad Sci U S A 2008; 105: 15136-15141.
37. Choi WS, Palmiter RD, Xia Z,. Loss of mitochondrial complex I activity potentiates dopamine neuron death induced by microtubule dysfunction in a Parkinson's disease model. J Cell Biol 2011; 192: 873-882.
38. Javitch JA, D'Amato RJ, Strittmatter SM, Snyder SH,. Parkinsonism-induced neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci U S A 1985; 82: 2173-2177.
39. Freire C, Koifman S,. Pesticide exposure and Parkinson's disease: epidemiological evidence of association. Neurotoxicology 2012; 33: 947-971.
40. Valente EM, Abou-Sleiman PM, Caputo V, et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 2004; 304: 1158-1160.
41. Clark IE, Dodson MW, Jiang C, et al. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 2006; 441: 1162-1166.
42. Park J, Lee SB, Lee S, et al. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 2006; 441: 1157-1161.
43. Vives-Bauza C, Zhou C, Huang Y, et al. PINK1-dependent recruitment of parkin to mitochondria in mitophagy. Proc Natl Acad Sci U S A 2010; 107: 378-383.
44. Narendra DP, Jin SM, Tanaka A, et al. PINK1 is selectively stabilized on impaired mitochondria to activate parkin. PLoS Biol 2010; 8: e1000298.
45. Narendra D, Tanaka A, Suen DF, Youle RJ,. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J Cell Biol 2008; 183: 795-803.
46. Poole AC, Thomas RE, Andrews LA, et al. The PINK1/parkin pathway regulates mitochondrial morphology. Proc Natl Acad Sci U S A 2008; 105: 1638-1643.
47. Yang Y, Ouyang Y, Yang L, et al. Pink1 regulates mitochondrial dynamics through interaction with the fission/fusion machinery. Proc Natl Acad Sci U S A 2008; 105: 7070-7075.
48. Wang X, Winter D, Ashrafi G, et al. PINK1 and parkin target Miro for phosphorylation and degradation to arrest mitochondrial motility. Cell 2011; 147: 893-906.
49. Shin JH, Ko HS, Kang H, et al. PARIS (ZNF746) repression of PGC-1alpha contributes to neurodegeneration in Parkinson's disease. Cell 2011; 144: 689-702.
50. Morais VA, Verstreken P, Roethig A, et al. Parkinson's disease mutations in PINK1 result in decreased complex I activity and deficient synaptic function. EMBO Mol Med 2009; 1: 99-111.
51. Gandhi S, Wood-Kaczmar A, Yao Z, et al. PINK1-associated Parkinson's disease is caused by neuronal vulnerability to calcium-induced cell death. Mol Cell 2009; 33: 627-638.
52. Heeman B, Van den Haute C, Aelvoet SA, et al. Depletion of PINK1 affects mitochondrial metabolism, calcium homeostasis and energy maintenance. J Cell Sci 2011; 124 (pt 7): 1115-1125.
53. Cho DH, Nakamura T, Fang J, et al. S-nitrosylation of Drp1 mediates beta-amyloid-related mitochondrial fission and neuronal injury. Science 2009; 324: 102-105.
54. Kamp F, Exner N, Lutz AK, et al. Inhibition of mitochondrial fusion by alpha-synuclein is rescued by PINK1, parkin and DJ-1. EMBO J 2010; 29: 3571-3589.
55. Nakamura K, Nemani VM, Azarbal F, et al. Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein alpha-synuclein. J Biol Chem 2011; 286: 20710-20726.
56. Song W, Chen J, Petrilli A, et al. Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity. Nat Med 2011; 17: 377-382.
57. Wang X, Su B, Lee HG, et al. Impaired balance of mitochondrial fission and fusion in Alzheimer's disease. J Neurosci 2009; 29: 9090-9103.
58. Tanaka A, Cleland MM, Xu S, et al. Proteasome and p97 mediate mitophagy and degradation of mitofusins induced by parkin. J Cell Biol 2010; 191: 1367-1380.
59. Duboff B, Gotz J, Feany MB,. Tau promotes neurodegeneration via DRP1 mislocalization in vivo. Neuron 2012; 75: 618-632.
60. Chen H, Chomyn A, Chan DC,. Disruption of fusion results in mitochondrial heterogeneity and dysfunction. J Biol Chem 2005; 280: 26185-26192.
61. Misko AL, Sasaki Y, Tuck E, et al. Mitofusin2 mutations disrupt axonal mitochondrial positioning and promote axon degeneration. J Neurosci 2012; 32: 4145-4155.
62. Van Laar VS, Berman SB,. The interplay of neuronal mitochondrial dynamics and bioenergetics: implications for Parkinson's disease. Neurobiol Dis 2013; 51: 43-55.
63. Verstreken P, Ly CV, Venken KJ, et al. Synaptic mitochondria are critical for mobilization of reserve pool vesicles at Drosophila neuromuscular junctions. Neuron 2005; 47: 365-378.
64. Kaufmann P, Engelstad K, Wei Y, et al. Dichloroacetate causes toxic neuropathy in MELAS: a randomized, controlled clinical trial. Neurology 2006; 66: 324-330.
65. Kruse SE, Watt WC, Marcinek DJ, et al. Mice with mitochondrial complex I deficiency develop a fatal encephalomyopathy. Cell Metab 2008; 7: 312-320.
66. Wredenberg A, Wibom R, Wilhelmsson H, et al. Increased mitochondrial mass in mitochondrial myopathy mice. Proc Natl Acad Sci U S A 2002; 99: 15066-15071.
67. McKenzie M, Liolitsa D, Akinshina N, et al. Mitochondrial ND5 gene variation associated with encephalomyopathy and mitochondrial ATP consumption. J Biol Chem 2007; 282: 36845-36852.
68. Powers WJ, Videen TO, Markham J, et al. Selective defect of in vivo glycolysis in early Huntington's disease striatum. Proc Natl Acad Sci U S A 2007; 104: 2945-2949.
69. Ciarmiello A, Cannella M, Lastoria S, et al. Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease. J Nucl Med 2006; 47: 215-222.
70. Kadir A, Almkvist O, Forsberg A, et al. Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease. Neurobiol Aging 2012; 33: 198 e1-198.e14.
71. Forster S, Grimmer T, Miederer I, et al. Regional expansion of hypometabolism in Alzheimer's disease follows amyloid deposition with temporal delay. Biol Psychiatry 2012; 71: 792-797.
72. Reiman EM, Chen K, Alexander GE, et al. Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism. Proc Natl Acad Sci U S A 2005; 102: 8299-8302.
73. Vlassenko AG, Vaishnavi SN, Couture L, et al. Spatial correlation between brain aerobic glycolysis and amyloid-beta (Abeta) deposition. Proc Natl Acad Sci U S A 2010; 107: 17763-17767.
74. Buchman AS, Wilson RS, Bienias JL, et al. Change in body mass index and risk of incident Alzheimer disease. Neurology 2005; 65: 892-897.
75. Djousse L, Knowlton B, Cupples LA, et al. Weight loss in early stage of Huntington's disease. Neurology 2002; 59: 1325-1330.
76. Chen H, Zhang SM, Hernan MA, et al. Weight loss in Parkinson's disease. Ann Neurol 2003; 53: 676-679.
77. Fex Svenningsen A, Shan WS, Colman DR, Pedraza L,. Rapid method for culturing embryonic neuron-glial cell cocultures. J Neurosci Res 2003; 72: 565-573.
78. Funfschilling U, Supplie LM, Mahad D, et al. Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity. Nature 2012; 485: 517-521.
79. Matsuda W, Furuta T, Nakamura KC, et al. Single nigrostriatal dopaminergic neurons form widely spread and highly dense axonal arborizations in the neostriatum. J Neurosci 2009; 29: 444-453.
80. Tiede LM, Cook EA, Morsey B, Fox HS,. Oxygen matters: tissue culture oxygen levels affect mitochondrial function and structure as well as responses to HIV viroproteins. Cell Death Dis 2011; 2: e246.
81. Zhu J, Aja S, Kim EK, et al. Physiological oxygen level is critical for modeling neuronal metabolism in vitro. J Neurosci Res 2012; 90: 422-434.
82. Dave KD, De Silva S, Ramboz S, et al. MJFF animal models 2: phenotypic characterization of the autosomal recessive (parkin, Pink-1 and DJ-1) gene knockout rat models of Parkinson's disease. Soc Neurosci 2012;Abstract #854.23.
83. Kitada T, Pisani A, Porter DR, et al. Impaired dopamine release and synaptic plasticity in the striatum of PINK1-deficient mice. Proc Natl Acad Sci U S A 2007; 104: 11441-11446.
84. Przedborski S, Jackson-Lewis V, Naini AB, et al. The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety. J Neurochem 2001; 76: 1265-1274.
85. Scheff SW, Price DA, Schmitt FA, et al. Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology 2007; 68: 1501-1508.
86. Li H, Li SH, Yu ZX, et al. Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington's disease mice. J Neurosci 2001; 21: 8473-8481.
87. Cheng HC, Ulane CM, Burke RE,. Clinical progression in Parkinson disease and the neurobiology of axons. Ann Neurol 2010; 67: 715-725.
88. Chu Y, Morfini GA, Langhamer LB, et al. Alterations in axonal transport motor proteins in sporadic and experimental Parkinson's disease. Brain 2012; 135 (pt 7): 2058-2073.
89. Zambonin JL, Zhao C, Ohno N, et al. Increased mitochondrial content in remyelinated axons: implications for multiple sclerosis. Brain 2011; 134 (pt 7): 1901-1913.
90. Ohno N, Kidd GJ, Mahad D, et al. Myelination and axonal electrical activity modulate the distribution and motility of mitochondria at CNS nodes of Ranvier. J Neurosci 2011; 31: 7249-7258.
91. Braak H, Del Tredici K,. Poor and protracted myelination as a contributory factor to neurodegenerative disorders. Neurobiol Aging 2004; 25: 19-23.
92. Shepherd GM, Harris KM,. Three-dimensional structure and composition of CA3 - >CA1 axons in rat hippocampal slices: implications for presynaptic connectivity and compartmentalization. J Neurosci 1998; 18: 8300-8310.
93. Kuznetsov AV, Margreiter R,. Heterogeneity of mitochondria and mitochondrial function within cells as another level of mitochondrial complexity. Int J Mol Sci 2009; 10: 1911-1929.
94. Chang DT, Honick AS, Reynolds IJ,. Mitochondrial trafficking to synapses in cultured primary cortical neurons. J Neurosci 2006; 26: 7035-7045.
95. Davey GP, Peuchen S, Clark JB,. Energy thresholds in brain mitochondria. Potential involvement in neurodegeneration. J Biol Chem 1998; 273: 12753-12757.
96. Musiek ES, Chen Y, Korczykowski M, et al. Direct comparison of fluorodeoxyglucose positron emission tomography and arterial spin labeling magnetic resonance imaging in Alzheimer's disease. Alzheimers Dement 2012; 8: 51-59.
97. Mandal PK,. Magnetic resonance spectroscopy (MRS) and its application in Alzheimer's disease. Concepts Magn Reson Part A 2007; 30: 40-65.
98. Mochel F, Durant B, Meng X, et al. Early alterations of brain cellular energy homeostasis in Huntington disease models. J Biol Chem 2012; 287: 1361-1370.
99. Viader A, Sasaki Y, Kim S, et al. Aberrant Schwann cell lipid metabolism linked to mitochondrial deficits leads to axon degeneration and neuropathy. Neuron 2013; 77: 886-898.
100. Wu M, Neilson A, Swift AL, et al. Multiparameter metabolic analysis reveals a close link between attenuated mitochondrial bioenergetic function and enhanced glycolysis dependency in human tumor cells. Am J Physiol Cell Physiol 2007; 292: C125-C136.
101. Yao J, Irwin RW, Zhao L, et al. Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 2009; 106: 14670-14675.
102. Herrero-Mendez A, Almeida A, Fernandez E, et al. The bioenergetic and antioxidant status of neurons is controlled by continuous degradation of a key glycolytic enzyme by APC/C-Cdh1. Nat Cell Biol 2009; 11: 747-752.
103. Bak LK, Obel LF, Walls AB, et al. Novel model of neuronal bioenergetics: postsynaptic utilization of glucose but not lactate correlates positively with Ca2+ signalling in cultured mouse glutamatergic neurons. ASN Neuro 2012; 4 (3).
104. Berg J, Hung YP, Yellen G,. A genetically encoded fluorescent reporter of ATP:ADP ratio. Nat Methods 2009; 6: 161-166.
105. Imamura H, Nhat KP, Togawa H, et al. Visualization of ATP levels inside single living cells with fluorescence resonance energy transfer-based genetically encoded indicators. Proc Natl Acad Sci U S A 2009; 106: 15651-15656.
106. Kovac S, Domijan AM, Walker MC, Abramov AY,. Prolonged seizure activity impairs mitochondrial bioenergetics and induces cell death. J Cell Sci 2012; 125 (pt 7): 1796-1806.
107. Takanaga H, Chaudhuri B, Frommer WB,. GLUT1 and GLUT9 as major contributors to glucose influx in HepG2 cells identified by a high sensitivity intramolecular FRET glucose sensor. Biochim Biophys Acta 2008; 1778: 1091-1099.
108. Bittner CX, Loaiza A, Ruminot I, et al. High resolution measurement of the glycolytic rate. Front Neuroenergetics 2010; 2.
109. Land SC, Porterfield DM, Sanger RH, Smith PJ,. The self-referencing oxygen-selective microelectrode: detection of transmembrane oxygen flux from single cells. J Exp Biol 1999; 202 (pt 2): 211-218.
110. Alavian KN, Li H, Collis L, et al. Bcl-xL regulates metabolic efficiency of neurons through interaction with the mitochondrial F1FO ATP synthase. Nat Cell Biol 2011; 13: 1224-1233.
111. Buckman JF, Reynolds IJ,. Spontaneous changes in mitochondrial membrane potential in cultured neurons. J Neurosci 2001; 21: 5054-5065.
112. Ward MW, Rego AC, Frenguelli BG, Nicholls DG,. Mitochondrial membrane potential and glutamate excitotoxicity in cultured cerebellar granule cells. J Neurosci 2000; 20: 7208-7219.
113. Brand MD, Nicholls DG,. Assessing mitochondrial dysfunction in cells. Biochem J 2011; 435: 297-312.
114. Reitzer LJ, Wice BM, Kennell D,. Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells. J Biol Chem 1979; 254: 2669-2676.
115. Rossignol R, Gilkerson R, Aggeler R, et al. Energy substrate modulates mitochondrial structure and oxidative capacity in cancer cells. Cancer Res 2004; 64: 985-993.
116. McNay EC, Fries TM, Gold PE,. Decreases in rat extracellular hippocampal glucose concentration associated with cognitive demand during a spatial task. Proc Natl Acad Sci U S A 2000; 97: 2881-2885.
117. Rex A, Bert B, Fink H, Voigt JP,. Stimulus-dependent changes of extracellular glucose in the rat hippocampus determined by in vivo microdialysis. Physiol Behav 2009; 98: 467-473.
118. Ames A III, Li YY, Heher EC, Kimble CR,. Energy metabolism of rabbit retina as related to function: high cost of Na+ transport. J Neurosci 1992; 12: 840-853.
119. Winkler BS, Arnold MJ, Brassell MA, Sliter DR,. Glucose dependence of glycolysis, hexose monophosphate shunt activity, energy status, and the polyol pathway in retinas isolated from normal (nondiabetic) rats. Invest Ophthalmol Vis Sci 1997; 38: 62-71.
120. Rotig A, Appelkvist EL, Geromel V, et al. Quinone-responsive multiple respiratory-chain dysfunction due to widespread coenzyme Q10 deficiency. Lancet 2000; 356: 391-395.
121. Duncan AJ, Bitner-Glindzicz M, Meunier B, et al. A nonsense mutation in COQ9 causes autosomal-recessive neonatal-onset primary coenzyme Q10 deficiency: a potentially treatable form of mitochondrial disease. Am J Hum Genet 2009; 84: 558-566.
122. Tarnopolsky MA, Beal MF,. Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders. Ann Neurol 2001; 49: 561-574.
123. Mercimek-Mahmutoglu S, Sinclair G, van Dooren SJ, et al. Guanidinoacetate methyltransferase deficiency: first steps to newborn screening for a treatable neurometabolic disease. Mol Genet Metab 2012; 107: 433-437.
124. Vos M, Esposito G, Edirisinghe JN, et al. Vitamin K2 is a mitochondrial electron carrier that rescues pink1 deficiency. Science 2012; 336: 1306-1310.
125. Choubey V, Safiulina D, Vaarmann A, et al. Mutant A53T alpha-synuclein induces neuronal death by increasing mitochondrial autophagy. J Biol Chem 2011; 286: 10814-10824.
126. Liu G, Zhang C, Yin J, et al. alpha-Synuclein is differentially expressed in mitochondria from different rat brain regions and dose-dependently down-regulates complex I activity. Neurosci Lett 2009; 454: 187-192.
127. Loeb V, Yakunin E, Saada A, Sharon R,. The transgenic over expression of alpha-synuclein and not its related pathology associates with complex I inhibition. J Biol Chem 2010; 285: 7334-7343.
128. Guzman JN, Sanchez-Padilla J, Wokosin D, et al. Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1. Nature 2010; 468: 696-700.
129. Hao LY, Giasson BI, Bonini NM,. DJ-1 is critical for mitochondrial function and rescues PINK1 loss of function. Proc Natl Acad Sci U S A 2010; 107: 9747-9752.
130. Wang X, Yan MH, Fujioka H, et al. LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1. Hum Mol Genet 2012; 21: 1931-1944.